The U.S. Food and Drug Administration (FDA) has approved the drug product LEUCOVORIN CALCIUM, identified by application number ANDA207241.
LEUCOVORIN CALCIUM is a human prescription drug supplied as a solution for intramuscular and intravenous administration. The product contains 100 mg of calcium folinate base per 10 mL (equivalent to 10 mg per mL) and is marketed under the brand and generic name LEUCOVORIN CALCIUM. The NDC is 63323-631-10.
The product is manufactured by Fresenius Kabi USA, LLC. The FDA submission was an original (ORIG) application, reviewed under standard priority, and received an approval status (AP) on March 14, 2018.
Regulatory UpdatesSep 10, 2026•1 min read
FDA Approves LEUCOVORIN CALCIUM (ANDA207241)
The FDA has granted approval for LEUCOVORIN CALCIUM (application ANDA207241) manufactured by Fresenius Kabi USA for prescription use.
Compiled by the PharmaCountry team · Source: FDA.gov
Ratings
(0)
(0)
(0)
(0)
(0)
More articles
View all insightsResearch & Reports
Global Finished Dosage Manufacturing Landscape 2026
Oct 5, 2026
Regulatory UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
Sep 28, 2026
AnalysisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
Sep 28, 2026
Leave your rating